
GlaxoSmithKline (GSK) has agreed to buy US vaccine technology firm Affinivax in deal worth up to 3.3 billion dollars (£2.6 billion).
It comes as the UK pharmaceutical business seeks to bolster its vaccine operation as part of a shake-up of its portfolio, including the spin-off of its consumer health business.